NeoGenomics Gets Dismissal of Cancer Test Misrepresentation Suit

NeoGenomics Inc. and its executives secured dismissal of a suit alleging they falsely promoted the company’s products as a “one-stop-shop” to test multiple cancer genes, a New York federal district court said.

Daniel Goldenberg, who sued on behalf of a proposed shareholder class, failed to plead particularized facts sufficiently alleging that NeoGenomics intentionally made misleading statements in violation of securities laws, Judge Valerie E. Caproni of the US District Court for the Southern District of New York said in a Friday order to dismiss.

The complaint fell short of showing the defendants’ statements or omissions “were made recklessly or with ...